Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/45—Transferases (2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

• Von Willebrand's disease is the most common inherited bleeding disorder and may occur in as many as 1 in 800 individuals.
• the von Willebrand factor (vWF) is heterogeneous multimeric plasma glycoprotein with two major functions. It facilitates platelet adhesion under conditions of high shear stress by linking platelet membrane receptors to vascular subendothelium. It also serves as the plasma carrier for factor Vm.
• the normal plasma level of vWF is 10 mg/L.
• the vWF activity is distributed among a series of plasma multimers with estimated molecular weights ranging from 400,000 to over 20 million.
• a single large vWF precursor subunit is synthesized in endothelial cells and megakaryocytes, where it is cleaved and assembled into the disulfide-linked multimers present in plasma, platelets, endothelial cells, and in the basement membrane of blood vessels. All of these pools of vWF contribute to the protein's main function, which is to promote attachment of platelets to areas of vessel injury.
• a highly active form of the protein is stored in secretory granules of platelets and of endothelial cells. When these cells sense tissue injury (e.g. by contact with thrombin) they instantly mobilize the stored vWF.
• vWF glycoprotein lb
• GPIIb glycoprotein lb
• vWF interacts with the GPIIb/TIIa on activated platelets and contributes to platelet spreading and aggregation.
• vWD is heterogeneous, there are certain clinical features that are common to all the syndromes.
• vWF ulcerative colitis
• vWF antigen In type I disease, there is a parallel decrease in vWF antigen, factor VHI activity, and ristocetin cofactor activity, with a normal spectrum of multimers detected by sodium dodecyl sulfate (SDS)-agarose gel electrophoresis.
• SDS sodium dodecyl sulfate
• vWD type II disease
• vWF vWD
• SDS-agarose electrophoresis SDS-agarose electrophoresis.
• the quantity of vWF antigen and the amount of associated factor VHI are usually normal.
• vWF antigen and the amount of associated factor VHI are usually normal.
• type Hb disease it is due to the inappropriate binding of vWF to platelets. This forms intravascular platelet aggregates that are rapidly cleared from the circulation, causing mild, cyclic thrombocytopenia.
• Type HI patients are usually the offspring of two parents with mild type I disease. However, in many cases, the parents are very mildly affected or are asymptomatic. Type HI patients may inherit a different abnormality from each parent (a doubly heterozygous or compound heterozygous state) or be homozygous for a single defect. Type HI patients have severe mucosal bleeding, no detectable vWF antigen or activity, and may have sufficiently low factor VHI that they have occasional hemarthroses like mild hemophiliacs.
• vWD Prior art treatment of vWD depends on the symptoms and the underlying type of disease.
• One type of treatment involves the use of cryoprecipitate, a plasma fraction enriched in vWF, or factor VHI concentrates, which retain high-molecular- weight vWF multimers (HUMATE-P®, KOATE HS®).
• a second therapeutic option, which avoid the use of plasma is use of l-desamino-8-D-arginine vasopressin (DDAVP), or desmopressin.
• DDAVP l-desamino-8-D-arginine vasopressin
• the present invention fills this need by administering factor XHI to patients with vWD, preferably in conjunction with either factor VHI concentrates, plasma cryoprecipitate enriched in vWF, DDAVP or desmopressin acetate.
• the method of the present invention improves upon the above-described treatment of von Willebrand's disease by administering factor XHI in conjunction with cryoprecipitate enriched in vWF, factor VHI concentrate, DDAVP or desmopressin acetate.
• the factor XHI can be administered at any time alone or at the same time as the other therapies either to stop a hemorrhage or for prophylaxis.
• Factor XHI also known as fibrin-stabilizing factor, circulates in the plasma at a concentration of about 20 mg/ml.
• the protein exists in plasma as a tetramer comprised of two A subunits and two B subunits. Each subunit has a molecular weight of 83,000 Da, and the complete protein has a molecular weight of approximately 330,000 Da.
• Factor XHI catalyzes the cross-linkage between the ⁇ -glutamyl and ⁇ -lysyl groups of different fibrin strands. The catalytic activity of factor XHI resides in the A subunits.
• the B subunits act as carriers for the A subunits in plasma factor XHI.
• Recombinant factor XHI can be produced according to the process described in
• the level of factor XHI in the plasma can also be increased by administering a factor X1H concentrate derived from human placenta called FIBROGAMMIN® (Aventis Corp.) or by administration of recombinant factor x .
• Administration of factor XHI to a subject is preferably intravenous.
• the administration may be by continuous infusion or by single or multiple boluses.
• a pharmaceutical composition comprising factor XHI can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier.
• a composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient.
• a suitable pharmaceutical composition of factor XHI will contain ImM EDTA, lOmM Glycine, 2% sucrose in water.
• An alternative formulation will be a factor XIH composition containing 20 mM histidine, 3% wt/volume sucrose, 2 mM glycine and .01% wt/vol. polysorbate, pH 8.
• the concentration of factor XIH should preferably be 1 - 10 mg/mL, more preferably about 5 mg/mL.
• Factor XIH can be administered intravenously, intramuscularly or subcutaneously to treat vWD.
• the levels of factor XIH in an individual can be determined by assays well known in the art such as the BERICHROM F XHI assay (Dade Behring Marburg GmbH, Marburg, Germany).
• the normal adult has an average of about 45 ml of plasma per kg of body weight.
• Each liter of blood has 1000 units (U) of factor XIH.
• a dose of .45 U kg would raise the level of factor XIH by about 1% compared to normal.
• One unit of factor XHI is about 10 micrograms (meg) of recombinant factor XIH, which contains only the dimerized, 'A 'subunit.
• HEMAFIL M human, plasma-derived
• HUMATE-P CONCENTRATE® human, plasma-derived

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23031409

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (1)

Citations (1)

• 2002
  • 2002-02-07 EP EP02714852A patent/EP1379271A1/en not_active Withdrawn
  • 2002-02-07 US US10/468,113 patent/US6979445B2/en not_active Expired - Fee Related
  • 2002-02-07 JP JP2002567345A patent/JP2004521129A/ja active Pending
  • 2002-02-07 CA CA002438761A patent/CA2438761A1/en not_active Abandoned
  • 2002-02-07 WO PCT/US2002/003742 patent/WO2002067980A1/en not_active Ceased

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events